NEWS: 公告在東京證券交易所JASDAQ標準市場新上市

市場調查報告書

先天性纖毛運動異常症(PCD)- 流行病學預測 2028年

Primary Ciliary Dyskinesia - Epidemiology Forecast to 2028

出版商 DelveInsight Business Research LLP 商品編碼 911517
出版日期 按訂單生產 內容資訊 英文 60 Pages
商品交期: 2-10個工作天內
價格
先天性纖毛運動異常症(PCD)- 流行病學預測 2028年 Primary Ciliary Dyskinesia - Epidemiology Forecast to 2028
出版日期: 按訂單生產內容資訊: 英文 60 Pages
簡介

主要7個國家(美國、英國、德國、法國、義大利、西班牙、日本)的先天性纖毛運動異常症(PCD)的2017年的患病數8萬815人估計。

本報告提供主要7個國家(美國、英國、德國、法國、義大利、西班牙、日本)的先天性纖毛運動異常症(PCD)市場調查,疾病概要,遺傳模式,患病數及診斷數的變化與預測詳細彙整。

目錄

第1章 重要洞察

第2章 先天性纖毛運動異常症(PCD)的流行病學

第3章 疾病背景和概要

  • 簡介
  • 原因
  • 危險因素
  • 徵兆與症狀

第4章 遺傳模式

  • 症狀
  • 遺傳學
  • 病理生理學
  • 相關疾病
  • 診斷方法
    • 診斷檢驗
    • 推薦診斷標準:各年齡
    • 非推薦檢驗
  • 歐洲呼吸系統學會(ERS)的先天性纖毛運動異常症(PCD)診斷的指南
  • 北美PCD財團的指南
  • 歐洲呼吸系統學會(ERS)和北美PCD財團的指南比較
  • 美國胸部學會(ATS)的先天性纖毛運動異常症(PCD)診斷的指南
  • 先天性纖毛運動異常症(PCD)診斷的未來展望

第5章 流行病學和患者人口

  • 主要調查結果

第6章 主要7個國家的先天性纖毛運動異常症(PCD)的總患病數

第7章 先天性纖毛運動異常症(PCD)的流行病學:各國

  • 美國
    • 假設和根據
    • 患病數
    • 診斷數
    • 臨床症狀
  • 歐洲5個國家
    • 德國
      • 假設和根據
      • 患病數
      • 診斷數
      • 臨床症狀
    • 法國
      • 假設和根據
      • 患病數
      • 診斷數
      • 臨床症狀
    • 義大利
      • 假設和根據
      • 患病數
      • 診斷數
      • 臨床症狀
    • 西班牙
      • 假設和根據
      • 患病數
      • 診斷數
      • 臨床症狀
    • 英國
      • 假設和根據
      • 患病數
      • 診斷數
      • 臨床症狀
  • 日本
    • 假設和根據
    • 患病數
    • 診斷數
    • 臨床症狀

第8章 附錄

  • 調查手法

第9章 DelveInsight的服務內容

第10章 免責聲明

第11章 關於DelveInsight

目錄
Product Code: DIEI0381

DelveInsight's 'Primary Ciliary Dyskinesia - Epidemiology Forecast to 2028' report delivers an in-depth understanding of the disease, historical & forecasted epidemiology as well as the market trends of Primary Ciliary Dyskinesia in the United States, EU5 (Germany, Spain, Italy, France and United Kingdom) and Japan.

Geography Covered

  • The United States
  • EU5 (Germany, France, Italy, Spain and the United Kingdom)
  • Japan

Study Period: 2017-2028

Primary Ciliary Dyskinesia - Disease Understanding and Treatment Algorithm

The DelveInsight Primary Ciliary Dyskinesia (PCD) market report gives the thorough understanding of the Primary Ciliary Dyskinesia (PCD) by including details such as disease definition, causes, symptoms, pathophysiology, and diagnostic trends. It also provides overview of treatment and management of the disease in the US, EU5 and Japan.

Primary ciliary dyskinesia (PCD) is an autosomal recessive genetic disorder caused by the impaired function of cilia of the respiratory tract epithelial cells, which may also involve other ciliated cells in the reproductive system of the male or female.

Primary Ciliary Dyskinesia (PCD) Epidemiology

The Primary Ciliary Dyskinesia epidemiology division provide the insights about historical and current patient pool and forecasted trend for every seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and the prevalence based on clinical manifestations in the US, EU5 and Japan.

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology (total diagnosed prevalent cases, and prevalence based on clinical manifestations) scenario of Primary Ciliary Dyskinesia in the 7MM covering United States, EU5 countries (Germany, Spain, Italy, France and United Kingdom) and Japan from 2017-2028.

According to DelveInsight, total prevalent population of Primary Ciliary Dyskinesia in seven major markets was found to be 80,815 in 2017. 

Primary Ciliary Dyskinesia (PCD) Report Insights

  • The report covers detailed overview of Primary Ciliary Dyskinesia explaining its causes, symptoms, pathophysiology, diagnosis and treatment patterns.
  • The report provides the insight about the historical and forecasted patient pool for 7 major markets covering the United States, EU5 (Germany, Spain, France, Italy, and UK) and Japan.
  • The Report highlights the unmet needs of Primary Ciliary Dyskinesia (PCD).
  • The Report helps to recognize the growth opportunities in the 7MM with respect to the patient population.
  • The report provides the segmentation of the disease epidemiology by total diagnosed prevalent patient population and clinical manifestations in 7MM.

Primary Ciliary Dyskinesia (PCD) Report Key Strengths

  • 10 Year Forecast
  • 7MM Coverage
  • Total diagnosed prevalent cases
  • Prevalence of PCD based on Clinical Manifestations

Primary Ciliary Dyskinesia (PCD) Report Assessment

  • Patient Segmentation based on clinical manifestations
  • Disease Risk & Burden
  • Factors driving growth in a specific patient population

Table of Contents

1. Key Insights

2. Primary Ciliary Dyskinesia: Epidemiology Overview at a Glance

3. Primary Ciliary Dyskinesia (PCD): Disease Background and Overview

  • 4.1 Introduction
  • 4.2 Causes
  • 4.3 Risk Factors
  • 4.4 Signs and Symptoms

4. Inheritance pattern

  • 5.1 Disease Manifestations
  • 5.2 Genetics
  • 5.3 Pathophysiology
    • 5.3.1 Structure and function of cilia
    • 5.3.2 Ciliary ultrastructural defects
    • 5.3.3 Proposed Pathogenesis of Primary Ciliary Dyskinesia Lung Disease
  • 5.4 Related Disorders
  • 5.5 Diagnostic Approach
    • 5.5.1 Diagnostic Tests
    • 5.5.2 Recommended PCD Diagnostic Criteria by Age
    • 5.5.3 Tests Not Recommended for PCD Diagnosis
    • 5.5.4 European Respiratory Society guidelines for the diagnosis of primary ciliary dyskinesia
  • 5.6 North American Primary Ciliary Dyskinesia (PCD) Foundation guidelines
  • 5.7 A comparison between the European Respiratory Society (ERS) and North American primary ciliary dyskinesia (PCD) Foundation guidelines
  • 5.8 American Thoracic Society (ATS) Guideline Aids in Diagnosing Primary Ciliary Dyskinesia
    • 5.8.1 Primary Ciliary Dyskinesia (PCD) Management
    • 5.8.2 Diagnostic algorithm for Primary Ciliary Dyskinesia
  • 5.9 Future Prospects of Primary Ciliary Dyskinesia Diagnosis

5. Epidemiology and Patient Population

  • 12.1 Key Findings

6. 7MM Total Prevalent Patient Population of PCD

7. Country Wise-Epidemiology of Primary Ciliary Dyskinesia

  • 7.1 United States
    • 7.1.1 Assumptions and Rationale
    • 7.1.2 Total Prevalent Population of Primary Ciliary Dyskinesia
    • 7.1.3 Total Diagnosed Population of Primary Ciliary Dyskinesia
    • 7.1.4 Clinical Manifestations of Primary Ciliary Dyskinesia
  • 7.2 EU5 Countries
    • 7.2.1 Assumptions and Rationale
  • 7.3 Germany
    • 7.3.1 Total Prevalent Population of Primary Ciliary Dyskinesia
    • 7.3.2 Total Diagnosed Population of Primary Ciliary Dyskinesia
    • 7.3.3 Clinical Manifestations of Primary Ciliary Dyskinesia
  • 7.4 France
    • 7.4.1 Total Prevalent Population of Primary Ciliary Dyskinesia
    • 7.4.2 Total Diagnosed Population of Primary Ciliary Dyskinesia
    • 7.4.3 Clinical Manifestations of Primary Ciliary Dyskinesia
  • 7.5 Italy
    • 7.5.1 Total Prevalent Population of Primary Ciliary Dyskinesia
    • 7.5.2 Total Diagnosed Population of Primary Ciliary Dyskinesia
    • 7.5.3 Clinical Manifestations of Primary Ciliary Dyskinesia
  • 7.6 Spain
    • 7.6.1 Total Prevalent Population of Primary Ciliary Dyskinesia
    • 7.6.2 Total Diagnosed Population of Primary Ciliary Dyskinesia
    • 7.6.3 Clinical Manifestations of Primary Ciliary Dyskinesia
  • 7.7 United Kingdom
    • 7.7.1 Total Prevalent Population of Primary Ciliary Dyskinesia
    • 7.7.2 Total Diagnosed Population of Primary Ciliary Dyskinesia
    • 7.7.3 Clinical Manifestations of Primary Ciliary Dyskinesia
  • 7.8 Japan
    • 7.8.1 Assumptions and Rationale
    • 7.8.2 Total Prevalent Population of Primary Ciliary Dyskinesia
    • 7.8.3 Total Diagnosed Population of Primary Ciliary Dyskinesia
    • 7.8.4 Clinical Manifestations of Primary Ciliary Dyskinesia

8. Appendix

  • 8.1 Report Methodology

9. DelveInsight Capabilities

10. Disclaimer

11. About DelveInsight

List of Tables

Table 1 Genes associated with Primary Ciliary Dyskinesia and corresponding ultrastructure

Table 2 Recommended Diagnostic Testing Methods for Primary Ciliary Dyskinesia

Table 3 Tests NOT Recommended for Diagnosing Primary Ciliary Dyskinesia

Table 4 Other Chronic Respiratory Conditions to Consider When Considering a Diagnosis of PCD

Table 5 Other Diseases Co-Segregating With PCD

Table 6 Recommended Diagnostic Testing Methods for Primary Ciliary Dyskinesia

Table 7 Tests NOT Recommended for Diagnosing Primary Ciliary Dyskinesia

Table 8 Other Chronic Respiratory Conditions to Consider When Considering a Diagnosis of PCD

Table 9 Other Diseases Co-Segregating With PCD

Table 10 Suggested Schedule of Investigations and Clinical Care in Primary Ciliary Dyskinesia

Table 11 Comparison of European Respiratory Society & North American PCD Foundation guidelines

Table 12 Total Prevalent Population of PCD in the 7MM (2017-2028)

Table 13 Total Prevalent Population of PCD in the US (2017-2028)

Table 14 Diagnosed Cases of PCD in the US (2017-2028)

Table 15 Clinical Mannifestations associated with Primary Ciliary Dyskinesia in the US (2017-2028)

Table 16 Situs Anomalies associated with Primary Ciliary Dyskinesia in the US (2017-2028)

Table 17 Lower Respiratory Tract Anomalies associated with Primary Ciliary Dyskinesia in the US (2017-2028)

Table 18 Upper Respiratory Tract Anomalies associated with Primary Ciliary Dyskinesia in the US (2017-2028)

Table 19 Other Manifestations associated with Primary Ciliary Dyskinesia in the US (2017-2028)

Table 20 Total Prevalent Population of PCD in Germany (2017-2028)

Table 21 Diagnosed Cases of PCD in Germany (2017-2028)

Table 22 Clinical Mannifestations associated with Primary Ciliary Dyskinesia in Germany (2017-2028)

Table 23 Situs Anomalies associated with Primary Ciliary Dyskinesia in the Germany (2017-2028)

Table 24 Lower Respiratory Tract Anomalies associated with Primary Ciliary Dyskinesia in Germany (2017-2028)

Table 25 Upper Respiratory Tract Anomalies associated with Primary Ciliary Dyskinesia in Germany (2017-2028)

Table 26 Other Manifestations associated with Primary Ciliary Dyskinesia in Germany (2017-2028)

Table 27 Total Prevalent Population of PCD in France (2017-2028)

Table 28 Diagnosed Cases of PCD in France (2017-2028)

Table 29 Clinical Mannifestations associated with Primary Ciliary Dyskinesia in France (2017-2028)

Table 30 Situs Anomalies associated with Primary Ciliary Dyskinesia in France (2017-2028)

Table 31 Lower Respiratory Tract Anomalies associated with Primary Ciliary Dyskinesia in France (2017-2028)

Table 32 Upper Respiratory Tract Anomalies associated with Primary Ciliary Dyskinesia in France (2017-2028)

Table 33 Other Manifestations associated with Primary Ciliary Dyskinesia in France (2017-2028)

Table 34 Total Prevalent Population of PCD in Italy (2017-2028)

Table 35 Diagnosed Cases of PCD in Italy (2017-2028)

Table 36 Clinical Manifestations associated with Primary Ciliary Dyskinesia in Italy (2017-2028)

Table 37 Situs Anomalies associated with Primary Ciliary Dyskinesia in Italy (2017-2028)

Table 38 Lower Respiratory Tract Anomalies associated with Primary Ciliary Dyskinesia in Italy (2017-2028)

Table 39 Upper Respiratory Tract Anomalies associated with Primary Ciliary Dyskinesia in Italy (2017-2028)

Table 40 Other Manifestations associated with Primary Ciliary Dyskinesia in Italy (2017-2028)

Table 41 Total Prevalent Population of PCD in Spain (2017-2028)

Table 42 Diagnosed Cases of PCD in Spain (2017-2028)

Table 43 Clinical Manifestations associated with Primary Ciliary Dyskinesia in Spain (2017-2028)

Table 44 Situs Anomalies associated with Primary Ciliary Dyskinesia in Spain(2017-2028)

Table 45 Lower Respiratory Tract Anomalies associated with Primary Ciliary Dyskinesia in Spain (2017-2028)

Table 46 Upper Respiratory Tract Anomalies associated with Primary Ciliary Dyskinesia in Spain (2017-2028)

Table 47 Other Manifestations associated with Primary Ciliary Dyskinesia in Spain (2017-2028)

Table 48 Total Prevalent Population of PCD in United Kingdom (2017-2028)

Table 49 Diagnosed Cases of PCD in United Kingdom (2017-2028)

Table 50 Clinical Mannifestations associated with Primary Ciliary Dyskinesia in the United Kingdom (2017-2028)

Table 51 Situs Anomalies associated with PCD in United Kingdom (2017-2028)

Table 52 Lower Respiratory Tract Anomalies associated with PCD in United Kingdom (2017-2028)

Table 53 Upper Respiratory Tract Anomalies associated with PCD in United Kingdom (2017-2028)

Table 54 Other Manifestations associated with PCD in United Kingdom (2017-2028)

Table 55 Total Prevalent Population of PCD in Japan (2017-2028)

Table 56 Diagnosed Cases of PCD in Japan (2017-2028)

Table 57 Clinical Manifestations associated with Primary Ciliary Dyskinesia in Japan (2017-2028)

Table 58 Situs Anomalies associated with Primary Ciliary Dyskinesia in Japan (2017-2028)

Table 59 Lower Respiratory Tract Anomalies associated with Primary Ciliary Dyskinesia in Japan (2017-2028)

Table 60 Upper Respiratory Tract Anomalies associated with Primary Ciliary Dyskinesia in Japan (2017-2028)

Table 61 Other Manifestations associated with Primary Ciliary Dyskinesia in Japan (2017-2028)

List of Figures

  • Figure 1: Total Prevalent Population of PCD in the 7 MM (2017)
  • Figure 2: Total Prevalent Population of PCD in the 7 MM (2028)
  • Figure 3: Organs affected by Primary Ciliary Dyskinesia
  • Figure 4: Risk Factors of Primary Ciliary Dyskinesis
  • Figure 5: Symptoms associated with Primary Ciliary Dyskinesia
  • Figure 6: Inheritance Pattern of PCD
  • Figure 7: The classical clinical phenotypes of Primary Ciliary Dyskinesia at various ages
  • Figure 8: The classical clinical phenotypes of Primary Ciliary Dyskinesia at various ages
  • Figure 9: Proposed pathogenesis of primary ciliary dyskinesia lung disease
  • Figure 10: Total Prevalent Patient Population of PCD in the 7MM (2017-2028)
  • Figure 11: Total Prevalent Population of PCD in the US (2017-2028)
  • Figure 12: Diagnosed Cases of PCD in the US (2017-2028)
  • Figure 13: Clinical Manifestations of PCD in the US (2017-2028)
  • Figure 14: Situs Anomalies associated with Primary Ciliary Dyskinesia in the US (2017-2028)
  • Figure 15: Lower Respiratory Tract Anomalies associated with Primary Ciliary Dyskinesia in the US (2017-2028)
  • Figure 16: Upper Respiratory Tract Anomalies associated with Primary Ciliary Dyskinesia in the US (2017-2028)
  • Figure 17: Other Manifestations associated with Primary Ciliary Dyskinesia in the US (2017-2028)
  • Figure 18: Total Prevalent Population of PCD in Germany (2017-2028)
  • Figure 19: Diagnosed Cases of PCD in Germany (2017-2028)
  • Figure 20: Clinical Manifestations of PCD in Germany (2017-2028)
  • Figure 21: Situs Anomalies associated with Primary Ciliary Dyskinesia in Germany (2017-2028)
  • Figure 22: Lower Respiratory Tract Anomalies associated with Primary Ciliary Dyskinesia in Germany (2017-2028)
  • Figure 23: Upper Respiratory Tract Anomalies associated with Primary Ciliary Dyskinesia in Germany (2017-2028)
  • Figure 24: Other Manifestations associated with Primary Ciliary Dyskinesia in Germany (2017-2028)
  • Figure 25: Total Prevalent Population of PCD in France (2017-2028)
  • Figure 26: Diagnosed Cases of PCD in France (2017-2028)
  • Figure 27: Clinical Manifestations of PCD in France (2017-2028)
  • Figure 28: Situs Anomalies associated with Primary Ciliary Dyskinesia in France (2017-2028)
  • Figure 29: Lower Respiratory Tract Anomalies associated with Primary Ciliary Dyskinesia in France (2017-2028)
  • Figure 30: Upper Respiratory Tract Anomalies associated with Primary Ciliary Dyskinesia in France (2017-2028)
  • Figure 31: Other Manifestations associated with Primary Ciliary Dyskinesia in France (2017-2028)
  • Figure 32: Total Prevalent Population of PCD in Italy (2017-2028)
  • Figure 33: Diagnosed Cases of PCD in Italy (2017-2028)
  • Figure 34: Clinical Manifestations of PCD in Italy (2017-2028)
  • Figure 35: Situs Anomalies associated with Primary Ciliary Dyskinesia in Italy (2017-2028)
  • Figure 36: Lower Respiratory Tract Anomalies associated with Primary Ciliary Dyskinesia in Italy (2017-2028)
  • Figure 37: Upper Respiratory Tract Anomalies associated with Primary Ciliary Dyskinesia in Italy (2017-2028)
  • Figure 38: Other Manifestations associated with Primary Ciliary Dyskinesia in Italy (2017-2028)
  • Figure 39: Total Prevalent Population of PCD in Spain (2017-2028)
  • Figure 40: Diagnosed Cases of PCD in Spain (2017-2028)
  • Figure 41: Clinical Manifestations of PCD in Spain (2017-2028)
  • Figure 42: Situs Anomalies associated with Primary Ciliary Dyskinesia in Spain (2017-2028)
  • Figure 43: Lower Respiratory Tract Anomalies associated with Primary Ciliary Dyskinesia in Spain (2017-2028)
  • Figure 44: Upper Respiratory Tract Anomalies associated with Primary Ciliary Dyskinesia in Spain (2017-2028)
  • Figure 45: Other Manifestations associated with Primary Ciliary Dyskinesia in Spain (2017-2028)
  • Figure 46: Total Prevalent Population of PCD in United Kingdom (2017-2028)
  • Figure 47: Diagnosed Cases of PCD in United Kingdom (2017-2028)
  • Figure 48: Clinical Manifestations of PCD in United Kingdom (2017-2028)
  • Figure 49: Situs Anomalies associated with PCD in United Kingdom (2017-2028)
  • Figure 50: Lower Respiratory Tract Anomalies associated with PCD in United Kingdom (2017-2028)
  • Figure 51: Upper Respiratory Tract Anomalies associated with PCD in United Kingdom (2017-2028)
  • Figure 52: Other Manifestations associated with PCD in United Kingdom (2017-2028)
  • Figure 53: Total Prevalent Population of PCD in Japan (2017-2028)
  • Figure 54: Diagnosed Cases of PCD in Japan (2017-2028)
  • Figure 55: Clinical Manifestations of PCD in Japan (2017-2028)
  • Figure 56: Situs Anomalies associated with Primary Ciliary Dyskinesia in Japan (2017-2028)
  • Figure 57: Lower Respiratory Tract Anomalies associated with Primary Ciliary Dyskinesia in Japan (2017-2028)
  • Figure 58: Upper Respiratory Tract Anomalies associated with Primary Ciliary Dyskinesia in Japan (2017-2028)
  • Figure 59: Other Manifestations associated with Primary Ciliary Dyskinesia in Japan (2017-2028)